CPC A61K 35/12 (2013.01) [A61K 39/00115 (2018.08); A61K 39/00117 (2018.08); A61K 39/001157 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); C07K 14/715 (2013.01); C12N 5/0634 (2013.01); C12N 5/0638 (2013.01); C12N 15/85 (2013.01); A61K 39/0011 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12N 15/63 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2510/00 (2013.01)] | 4 Claims |
1. An immune system cell comprising a chimeric cytokine receptor comprising a cytokine-binding exodomain and a signal transducing endodomain, wherein the exodomain is selected from the group consisting of interleukin (IL)10 receptor exodomain, IL13 receptor exodomain, transforming growth factor (TGF)beta receptor exodomain, IL6 receptor exodomain, IL8 receptor exodomain, and a combination thereof, and wherein the endodomain is selected from the group consisting of IL2 receptor endodomain, IL7 receptor endodomain, IL15 receptor endodomain, and a combination thereof,
or wherein the exodomain is IL4 receptor exodomain and the endodomain is IL7 receptor endodomain.
|